

## Case Report Section

Paper co-edited with the European LeukemiaNet

# t(4;12)(q11;p13) in an acute myeloid leukemia without maturation with myelodysplasia

Jean-Philippe Rault

Laboratoire d'Hématologie et de Génétique, Hôpital de Metz, CHR Metz-Thionville, Metz, France

Published in Atlas Database: September 2005

Online updated version: <http://AtlasGeneticsOncology.org/Reports/0412RaultID100014.html>  
DOI: 10.4267/2042/38283

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.  
© 2006 Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Clinics

Age and sex: 67 years old male patient.  
Previous History : no preleukemia; no previous malignant disease; no inborn condition of note.  
Organomegaly : no hepatomegaly ; no splenomegaly ; no enlarged lymph nodes ; no central nervous system involvement.

### Blood

WBC:  $3,6 \times 10^9/l$ ; Hb: 8,6 g/dl; platelets:  $151 \times 10^9/l$ ; blasts: 56%.  
Bone marrow: Cellularity fewer than usual. Rare megakaryocytes, presence of micromegakaryocytes. Infiltration by blasts at a level of 58% with myeloid features. Dysgranulopoiesis >10 % of non erythroblastic cells.

### Cytopathology classification

Immunophenotype: CD34 (85%), HLA DR (91%) and myeloid cluster: CD11c (7%), CD13 (97%), CD13c (99%), CD33 (98%), CD117 (81%), MPO 5% and only one lymphoid cluster CD7 (87%). Conclusion: immature myeloid population. Phenotype FAB M0.  
Rearranged Ig or Tcr: Not done.  
Pathology: Secondary Acute Respiratory disease due to a bilateral alveolar pneumopathy on June 2005, without suitable microbiological data, following an aplasia phase with fever at D+16 (chemotherapy induction step).  
Electron microscopy: No.  
Precise diagnosis: AML type Mo with myelodysplasia.


### Survival

Date of diagnosis: 04-2005.  
Treatment: LAM SA 2002 Protocol. Idarubicine: 15mg

per day from J1 to J5 / Aracytine: 180 mg per day from J1 to J7 / Belustine: 360 mg only at J1 then Aracytine and Idarubicine each three month during 15 days (6 cures).  
Complete remission: Yes during induction phase.  
Treatment related death: No.  
Relapse: No.  
Status: Alive 08-2005.  
Survival: 5 months.

### Karyotype

Sample: Bone marrow; Culture time: 24/48h; Banding: R.  
Results: 46, XY, t(4;12)(q11;p13.1) [27] / 46, XY [3]  
Karyotype at relapse: No relapse.



t(4;12)(q11;p13.1) R-banding

### Comments

No AML/ETO t(8;21)(q22;q22) translocation, no split of MLL performed by FISH analysis.

## References

Nathan PC, Chun K, Abdelhaleem M, Malkin D. Isochromosome (17)(q10) and translocation (4;12)(q12;p13) in a child with acute myeloid leukemia. *Cancer Genet Cytogenet.* 2001 Nov;131(1):82-5.

---

*This article should be referenced as such:*

Rault JP. *t(4;12)(q11;p13) in an acute myeloid leukemia without maturation with myelodysplasia.* *Atlas Genet Cytogenet Oncol Haematol.*2006;10(1):58-59.

---